ImmunoCellular Therapeutics Ltd
EOM Pharmaceuticals Holdings, Inc., a clinical-stage biotechnology company, focuses on the development of drugs to transform therapeutic paradigms and enhance quality of life in patients suffering from debilitating and deadly diseases in the United States. The company's lead compound is EOM613, a peptide nucleic-acid solution with both anti-inflammatory and pro-inflammatory broad spectrum cytokin… Read more
ImmunoCellular Therapeutics Ltd (IMUC) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2022: 0.164x
Based on the latest financial reports, ImmunoCellular Therapeutics Ltd (IMUC) has a cash flow conversion efficiency ratio of 0.164x as of December 2022.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-687.93K) by net assets ($-4.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
ImmunoCellular Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2005–2024)
This chart illustrates how ImmunoCellular Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
ImmunoCellular Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ImmunoCellular Therapeutics Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Teras Resources Inc
PINK:TRARF
|
0.176x |
|
Captivision Inc. Warrant
NASDAQ:CAPTW
|
0.085x |
|
Thiensurat Public Company Limited
BK:TSR
|
-0.011x |
|
Suny Cellular Communication Ltd
TA:SNCM
|
0.113x |
|
Cinis Fertilizer AB
ST:CINIS
|
-0.134x |
|
Tijaria Polypipes Limited
NSE:TIJARIA
|
-0.155x |
|
BDCC
PINK:BDCC
|
0.038x |
|
ReTo Eco-Solutions Inc
NASDAQ:RETO
|
-0.047x |
Annual Cash Flow Conversion Efficiency for ImmunoCellular Therapeutics Ltd (2005–2024)
The table below shows the annual cash flow conversion efficiency of ImmunoCellular Therapeutics Ltd from 2005 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-617.86K | $-2.68 Million | 4.337x | +1636.16% |
| 2023-12-31 | $-5.69 Million | $-1.42 Million | 0.250x | -60.11% |
| 2022-12-31 | $-4.19 Million | $-2.62 Million | 0.626x | -56.12% |
| 2021-12-31 | $-1.62 Million | $-2.31 Million | 1.427x | +114.95% |
| 2020-12-31 | $129.58K | $-1.24 Million | -9.547x | -166.18% |
| 2017-12-31 | $4.65 Million | $-16.67 Million | -3.587x | -10.71% |
| 2016-12-31 | $6.13 Million | $-19.86 Million | -3.240x | -269.58% |
| 2015-12-31 | $21.72 Million | $-19.04 Million | -0.877x | -105.47% |
| 2014-12-31 | $23.29 Million | $-9.94 Million | -0.427x | -28.53% |
| 2013-12-31 | $26.47 Million | $-8.79 Million | -0.332x | +38.15% |
| 2012-12-31 | $23.07 Million | $-12.38 Million | -0.537x | +72.83% |
| 2011-12-31 | $3.23 Million | $-6.38 Million | -1.975x | -8.46% |
| 2010-12-31 | $2.34 Million | $-4.25 Million | -1.821x | +7.16% |
| 2009-12-31 | $1.10 Million | $-2.15 Million | -1.962x | -196.46% |
| 2008-12-31 | $2.94 Million | $-1.95 Million | -0.662x | -262.57% |
| 2007-12-31 | $5.00 Million | $-912.00K | -0.182x | +93.44% |
| 2006-12-31 | $189.66K | $-527.72K | -2.782x | -3.05% |
| 2005-12-31 | $20.26K | $-54.71K | -2.700x | -- |